Selected acute phase proteins and interleukin-6 in systemic lupus erythematosus patients treated with low doses of quinagolide

References

• Castell JV, Gomez- Lechon MJ, David M, Andus T, Geiger T, Trullenque R, Fabra R, Heinrich PC. Interleukin-6 is the major regulator of acute phase protein synthesis in adult human hepatocytes. FEBS Lett 1989; 242: 237–239
   PubMed Web of Science ®Google Scholar
• Hirano T. Interleukin-6 and its relation to inflammation and disease. Clin Immunol Immunopathol 1992; 62: 60–65
   PubMedGoogle Scholar
• Linker-Israeli M, Deans RJ, Wallace DJ, Prehn J, Ozeri-Chen T, Klinenberg JR. Elevated levels of endogenous IL-6 in systemic lupus erythematosus. A putative role in pathogenesis. J Immunol 1991; 147: 117–123
   PubMed Web of Science ®Google Scholar
• Spronk PE, ter Borg EJ, Limburg PC, Kallenberg CGM. Plasma concentration of IL-6 systemic lupus erythematosus; an indicator of disease activity. Clin Exp Immunol 1992; 90: 106–110
   PubMed Web of Science ®Google Scholar
• Robak E, Sysa-Jędrzejewska A, Stepien H, Robak T. Circulating interleukin-6 type cytokines in patients with systemic lupus erythematosus. Eur Cytokine Netw 1997; 8: 281–286
   PubMed Web of Science ®Google Scholar
• Hrycek A, Cieślik P, Tustanowski J, Nowak S, Jedynak P. Selected serum cytokines in systemic lupus erythematosus treated with quinagolide. Lupus 2001; 10: 424–430
   PubMedGoogle Scholar
• Lacki JK, Samborski W, Mackiewicz SH. Interleukin-10 and interleukin-6 in lupus erythematosus and rheumatoid arthritis, correlation with acute phase proteins. Clin Rheumatol 1997; 16: 275–278
   PubMed Web of Science ®Google Scholar
• Swaak AJG, van Rooyen A, Aarden LA. Interleukin-6 (IL-6) and acute phase proteins in the disease course of patients with systemic lupus erythematosus. Rheumatol Int 1989; 8: 263–268
   PubMed Web of Science ®Google Scholar
• Metsarinne KP, Nordstrom DCE, Konttinen YT, Teppo AM, Fyhrquist FY. Plasma interleukin-6 and renin substrate in reactive arthritis, rheumatoid arthritis and systemic lupus erythematosus. Rheumatol Int 1992; 12: 93–96
   PubMedGoogle Scholar
• Spangelo BL, Judd AM, Isakson PC, MacLeod RM. Interleukin-6 stimulates anterior pituitary hormone release in vitro. Endocrinology 1989; 125: 575–577
   PubMed Web of Science ®Google Scholar
• Walker SE, Jara JL. Prolactin, a pituitary hormone that modifies immune responses. 1998; 7: 371–375, Proceedings of the mini-symposium on prolactin and SLE, held at the 5th International Conference on Systemic Lupus Erythematosus, Cancun, Mexico. Lupus
   Google Scholar
• Mc Murray RW, Weidensaul D, Allen SH, Walker SE. Efficcy of bromocriptine in an open label therapeutic trial for systemic lupus erythematosus. J Rheumatol 1995; 22: 2084–2091
   PubMedGoogle Scholar
• Alvarez-Nemegyei J, Cobarrubias-Cobos A, Escalante-Triay F, Sosa-Munoz J, Miranda JM, Jara LJ. Bromocriptine in systemic lupus erythematosus: A double-blind, randomized, placebo-controlled study. Lupus 1998; 7: 414–419
   PubMed Web of Science ®Google Scholar
• Walker SE, Smarr KL, Parker JC, Weidensaul DN, Nelson W, McMurray RW. Mood states and disease activity in patients with systmic lupus erythematosus treated with bromocriptine. Lupus 2000; 9: 527–533
   PubMed Web of Science ®Google Scholar
• McMurray RW, Allen SH, Braun AL, Rodriguez F, Walker SE. Longstanding hyperprolactinemia associated with systemic lupus erythematosus: Possible hormonal stimulation of an autoimmune disease. J Rheumatol 1994; 21: 843–850
   PubMedGoogle Scholar
• Walker SE, Allen SH, Hoffman RW, McMurray RW. Prolactin: A stimulator of disease activity in systemic lupus erythematosus. Lupus 1995; 4: 3–9
   PubMed Web of Science ®Google Scholar
• Funauchi M, Ikoma S, Enomoto H, Sugiyama M, Ohno M, Hamada K, Kanamaru A. Prolactin modulates the disease activity of systemic lupus erythematosus accompanied by prolactinoma. Clin Exp Rheumatol 1998; 16: 479–482
   PubMedGoogle Scholar
• Yang XY, Liang LQ, Xu HS, He M, Yao SZ, Zhan ZP, Ye YJ. Efficacy of oral bromocriptine in protecting the postpartum systemic lupus erythematosus patients from disease relapse. Zhonghua Nei Ke Za Zhi 2003; 42: 621–624
   PubMedGoogle Scholar
• Bombardier C, Gladman DD, Urowitz MB, Caron D, Chang CH. Derivation of the SLEDAI. A disease activity index for lupus patients. The committee on prognosis studies in SLE. Arthritis Rheum 1992; 35: 630–640
   PubMed Web of Science ®Google Scholar
• Tan EM, Cohen AS, Fries JF, Masi AT, McShane DJ, Rothfield NF, Schaller JG, Talal N, Winchester RJ. The revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1982; 25: 1271–1277
   PubMed Web of Science ®Google Scholar
• Hochberg MC. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1997; 40: 1725
   PubMed Web of Science ®Google Scholar
• Pepys MB, Lanham JG, De Beer FC. C-reactive protein in SLE. Clin Rheum Dis 1982; 8: 91–103
   PubMedGoogle Scholar
• Gordon C, Emery P. Cytokines and the acute phase response in SLE. Lupus 1993; 2: 345–347
   PubMedGoogle Scholar
• Russell AI, Cunninghame-Graham DS, Shepherd C, Roberton CA, Whittaker J, Meeks J, Powell RJ, Isenberg DA, Walport MJ, Vyse TJ. Polymorphism at the C-reactive protein locus influences gene expression and predisposes to systemic lupus erythematosus. Hum Mol Genet 2004; 13: 137–147
   PubMed Web of Science ®Google Scholar
• Ablij HC, Meinders AE. C-reactive protein: History and revival. Eur J Int Med 2002; 13: 412–422
   PubMedGoogle Scholar
• Pepys MB. C-reactive protein fifty years on. Lancet 1981; 21: 653–657
   Google Scholar
• Hrycek A, Siekiera M, Cieślik P, Szkróbka W. The HLA-DRB1, HLA-DQB1 alleles and gene polymorphism of selected cytokines in patients with SLE. Rheumatol Int 2005; 26: 1–6
   PubMed Web of Science ®Google Scholar
• Gabay C, Roux-Lombard P, de Moerloose P, Dayer JM, Vischer T, Guerne PA. Absence of correlation between interleukin-6 and C-reactive protein blood levels in systemic lupus erythematosus compared with rheumatoid arthritis. J Rheumatol 1993; 20: 815–821
   PubMedGoogle Scholar
• Pacilio M, Migliaresi S, Meli R, Ambrosone L, Bigliardo B, di Carlo R. Elevated bioactive prolactin levels in systemie lupus erythematosus-association with disease activity. J Rheumatol 2001; 28: 2216–2221
   PubMed Web of Science ®Google Scholar
• Jacobi AM, Rohde W, Ventz M, Riemekasten G, Burmester GR, Hiepe F. Enhanced serum prolactin (PRL) in patients with systemic lupus erythematosus: PRL levels are related to the disease activity. Lupus 2001; 10: 554–561
   PubMed Web of Science ®Google Scholar
• Neidhart M. Elevated serum prolactin or elevated prolactin/cortisol ratio are associated with autoimmune processes in systemic lupus erythematosus and other connective tissue diseases. J Rheumatol 1996; 23: 476–481
   PubMed Web of Science ®Google Scholar
• Jara LJ, Gomez-Sanchez C, Silveira LH, Martinez-Osuna P, Vasey FB, Espinoza LR. Hyperprolactinemia in systemic lupus erythematosus: Association with disease activity. Am J Med Sci 1992; 303: 222–226
   PubMed Web of Science ®Google Scholar
• Jimena P, Aguirre MA, Lopez-Curbelo A, de Andres M, Garcia-Courtay C, Cuadrado MJ. Prolactin levels in patients with systemic lupus erythematosus: A case controlled study. Lupus 1998; 7: 383–386
   PubMed Web of Science ®Google Scholar
• Morikawa K, Oseko F, Morikawa S. Immunosuppressive activity of bromocriptine on human T lymphocyte function in vitro. Clin Exp Immunol 1994; 95: 514–518
   PubMed Web of Science ®Google Scholar
• Tseng YH, Kessler MA, Schuler LA. Regulation of interleukin IL-1 alpha, IL-1beta and IL-6 expression by growth hormone and prolactin in bovine thymic stromal cells. Mol Cell Endocrinol 1997; 128: 117–127
   PubMed Web of Science ®Google Scholar
• Vera-Lastra O, Mendez C, Jara LJ, Cisneros M, Medina G, Ariza R, Espinoza LR. Correlation of prolactin serum concentrations with clinical activity and remission in patients with systemic lupus erythematosus. Effect of conventional treatment. J Rheumatol 2003; 30: 2140–2146
   PubMed Web of Science ®Google Scholar
• Ostendorf B, Fischer R, Santen R, Schmitz-Linneweber B, Specker Ch, Schneider M. Hyperprolactinemia in systemic lupus erythematosus?. Scand J Rheumatol 1996; 25: 97–102
   PubMed Web of Science ®Google Scholar
• Buskila D, Sukenik S, Shoenfeld Y. The possible role of prolactin in autoimmunity. Am J Reprod Immunol 1991; 26: 118–123
   PubMed Web of Science ®Google Scholar
• Rovensky J, Jurankova E, Rauova L, Blazickova S, Lukac J, Veselkova Z, Jezova D, Vigas M. Relationship between endocrine, immune and clinical variables in patients with systemic lupus erythematosus. J Rheumatol 1997; 24: 2330–2334
   PubMed Web of Science ®Google Scholar
• Hrycek A, Pochopień-Kenig G. Disease activity indices applied in systemic lupus erythematosus. Pol Arch Med Wew; CXI 2004; 3: 383–390
   Google Scholar